The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)
Public ClinicalTrials.gov record NCT01250548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis. The investigators will be collecting information in this study to help us determine - * the safety of apremilast in patients with active rheumatoid arthritis * how long it takes for patients with active rheumatoid arthritis to respond to apremilast * how long the effects of apremilast last after the treatment has ended.
Study identification
- NCT ID
- NCT01250548
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- May 31, 2014
- Completion
- May 31, 2014
- Last update posted
- Sep 2, 2014
2010 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baylor Research Institute - Arthritis Care and Research Center | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Rheumatoid Arthritis trials
Other public records listing Rheumatoid Arthritis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07137598: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) Recruiting
- NCT04817969: Persona Ti-Nidium Post-Market Clinical Follow-up Active, not recruiting
- NCT07620392: An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis Recruiting
- NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD Active, not recruiting
- NCT07704580: Phase 1b/2 Study of IV Sarilumab in Adult With RA Recruiting
- NCT07293871: Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01250548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2014 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01250548 live on ClinicalTrials.gov.